About Cabling Installation & Maintenance

Our mission: Bringing practical business and technical intelligence to today's structured cabling professionals

For more than 30 years, Cabling Installation & Maintenance has provided useful, practical information to professionals responsible for the specification, design, installation and management of structured cabling systems serving enterprise, data center and other environments. These professionals are challenged to stay informed of constantly evolving standards, system-design and installation approaches, product and system capabilities, technologies, as well as applications that rely on high-performance structured cabling systems. Our editors synthesize these complex issues into multiple information products. This portfolio of information products provides concrete detail that improves the efficiency of day-to-day operations, and equips cabling professionals with the perspective that enables strategic planning for networks’ optimum long-term performance.

Throughout our annual magazine, weekly email newsletters and 24/7/365 website, Cabling Installation & Maintenance digs into the essential topics our audience focuses on.

  • Design, Installation and Testing: We explain the bottom-up design of cabling systems, from case histories of actual projects to solutions for specific problems or aspects of the design process. We also look at specific installations using a case-history approach to highlight challenging problems, solutions and unique features. Additionally, we examine evolving test-and-measurement technologies and techniques designed to address the standards-governed and practical-use performance requirements of cabling systems.
  • Technology: We evaluate product innovations and technology trends as they impact a particular product class through interviews with manufacturers, installers and users, as well as contributed articles from subject-matter experts.
  • Data Center: Cabling Installation & Maintenance takes an in-depth look at design and installation workmanship issues as well as the unique technology being deployed specifically for data centers.
  • Physical Security: Focusing on the areas in which security and IT—and the infrastructure for both—interlock and overlap, we pay specific attention to Internet Protocol’s influence over the development of security applications.
  • Standards: Tracking the activities of North American and international standards-making organizations, we provide updates on specifications that are in-progress, looking forward to how they will affect cabling-system design and installation. We also produce articles explaining the practical aspects of designing and installing cabling systems in accordance with the specifications of established standards.

Cabling Installation & Maintenance is published by Endeavor Business Media, a division of EndeavorB2B.

Contact Cabling Installation & Maintenance

Editorial

Patrick McLaughlin

Serena Aburahma

Advertising and Sponsorship Sales

Peter Fretty - Vice President, Market Leader

Tim Carli - Business Development Manager

Brayden Hudspeth - Sales Development Representative

Subscriptions and Memberships

Subscribe to our newsletters and manage your subscriptions

Feedback/Problems

Send a message to our general in-box

 

BioNxt Advances Semaglutide Oral Dissolvable Film (ODF) Program with Successful Proof-of-Concept and Prototype Development

VANCOUVER, BC / ACCESS Newswire / September 15, 2025 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:XPHYF)(FSE:4XT) is pleased to announce the successful completion of proof-of-concept trials for its Semaglutide oral dissolvable film ("ODF") program at Vektor Pharma TF GmbH ("Vektor Pharma"), the Company's wholly owned German subsidiary.

Over the past several weeks, multiple proprietary film platforms were evaluated at Vektor Pharma. One of these in-house platforms achieved highly promising results, generating first prototypes of Semaglutide-ODF formulations with strong performance characteristics. The prototypes demonstrated rapid disintegration, homogeneous film quality, good processability during manufacturing, and favorable mechanical properties. These results confirm the suitability of BioNxt's thin film technology for complex peptide formulations and provide a solid foundation for further development.

This achievement marks a key advancement in the program and provides positive momentum as the project advances into its next stage.

"Achieving positive proof-of-concept results with first prototypes in-hand represents an important milestone for BioNxt," said Hugh Rogers, CEO of BioNxt Solutions. "These results validate our approach and allow us to proceed with greater confidence as we optimize the formulation, secure intellectual property, and prepare for preclinical testing."

Patent Filing and Next-Stage Development

Building on the successful prototypes, BioNxt is preparing to file a patent application for the Semaglutide ODF in the coming months. Under the supervision of Vektor Pharma, development will now transition toward refining the formulation to optimize performance and absorption potential, while also initiating stability studies, advancing scale-up work, and preparing the product for preclinical evaluation.

These efforts are expected to continue through late 2025 and will culminate in a preclinical animal study anticipated to begin in early 2026. The study will evaluate the pharmacological performance and overall suitability of the product. Looking further ahead, BioNxt intends to manufacture an Investigational Medicinal Product (IMP) to support a pilot clinical study targeted for the second half of 2026.

Addressing the Expanding GLP-1 Market

Semaglutide, currently marketed under the brand names Ozempic® and Rybelsus®, is a GLP-1 receptor agonist approved for type 2 diabetes and obesity. Global demand for GLP-1 therapies is expanding rapidly, with Semaglutide alone generating more than USD 29.3 billion in sales in 2024. BioNxt's oral thin film delivery format is designed to offer patients a non-invasive, accessible, and compliance-friendly alternative to existing injectable and tablet-based options.

Semaglutide represents the lead candidate in BioNxt's GLP-1 ODF portfolio, which is expected to include additional GLP-1-based therapies developed on the Company's proprietary thin film platform.

About BioNxt Solutions Inc.

BioNxt Solutions Inc. is a bioscience innovator focused on next-generation drug delivery platforms, diagnostic screening systems, and active pharmaceutical ingredient development. Its proprietary platforms include sublingual thin films, transdermal patches, oral tablets, and a new targeted chemotherapy platform designed to deliver cancer drugs directly to tumors while reducing side effects.

With research and development operations in North America and Europe, BioNxt is advancing regulatory approvals and commercialization efforts, primarily focused on European markets. BioNxt is committed to improving healthcare by delivering precise, patient-centric solutions that enhance treatment outcomes worldwide.

BioNxt is listed on the Canadian Securities Exchange: BNXT, OTC Markets: BNXTF and trades in Germany under WKN: A3D1K3. To learn more about BioNxt, please visit www.bionxt.com.

Investor Relations & Media Contact

Hugh Rogers, Co-Founder, CEO and Director
Email: investor.relations@bionxt.com
Phone: +1 604.250.6162

Web: www.bionxt.com
LinkedIn: https://www.linkedin.com/company/bionxt-solutions
Instagram: https://www.instagram.com/bionxt

Cautionary Statement Regarding "Forward-Looking" Information

This press release contains "forward-looking information" and "forward-looking statements" within the meaning of applicable Canadian securities laws (collectively, "forward-looking information"). Forward-looking information includes, but is not limited to, statements related to the Company's oral thin film (ODF) development program for Semaglutide; the anticipated timing and outcomes of formulation studies; the potential for future patent filings; market growth projections; and the broader applicability of the Company's drug delivery technologies.

Forward-looking information is based on management's reasonable assumptions, expectations, estimates, and projections as of the date of this press release. Such statements are subject to various known and unknown risks, uncertainties, and other factors - many of which are beyond the Company's control - that may cause actual results, performance, or achievements to differ materially from those expressed or implied by such forward-looking information. These risks and uncertainties include, but are not limited to: scientific and technical development risks; manufacturing and scalability risks; intellectual property protection; regulatory approval processes; competition in the GLP-1 drug market; and general economic, financial, and market conditions.

Readers are cautioned not to place undue reliance on forward-looking information. Although the Company believes the expectations and assumptions reflected in such statements are reasonable, there can be no assurance that they will prove to be correct. Except as required by applicable securities laws, the Company undertakes no obligation to update or revise any forward-looking information, whether as a result of new information, future events, or otherwise.

Ozempic® and Rybelsus® are registered trademarks of Novo Nordisk A/S and are not affiliated with or developed by BioNxt Solutions Inc.

SOURCE: BioNxt Solutions Inc.



View the original press release on ACCESS Newswire

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.